Post‐Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery
Neurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to protectdegenerating dopaminergic neurons. Here, we performed post-mortem studies on two patients with advanced Parkinson's disease that survived 10 years following AA...
Saved in:
| Published in: | Movement disorders Vol. 38; no. 9; pp. 1728 - 1736 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.09.2023
|
| Subjects: | |
| ISSN: | 0885-3185, 1531-8257, 1531-8257 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Neurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to protectdegenerating dopaminergic neurons.
Here, we performed post-mortem studies on two patients with advanced Parkinson's disease that survived 10 years following AAV-neurturin gene (Cere120) delivery to verify long-term effects of trophic factor neurturin.
Cere120 was delivered to the putamen bilaterally in one case and to the putamen plus substantia nigra bilaterally in the second. Immunohistochemistry was used to examine neurturin, Rearranged during transfection(RET), phosphor-S6, and tyrosine hydroxylase expressions, inflammatory reactions, and α-synuclein accumulation.
In both patients there was persistent, albeit limited, neurturin expression in the putamen covering 1.31% to 5.92% of the putamen. Dense staining of tyrosine hydroxylase-positive fibers was observed in areas that contained detectable neurturin expression. In substantia nigra, neurturin expression was detected in 11% of remaining melanin-containing neurons in the patient with combined putamenal and nigral gene delivery, but not in the patient with putamenal gene delivery alone. Tyrosine hydroxylase positive neurons were 66% to 84% of remaining neuromelanin neurons in substantia nigra with Cere120 delivery and 23% to 24% in substantia nigra without gene delivery. More RET and phosphor-S6 positive neurons were observed in substantia nigra following nigral Cere120. Inflammatory and Lewy pathologies were similar in substantia nigra with or without Cere120 delivery.
This study provides evidence of long-term persistent transgene expression and bioactivity following gene delivery to the nigrostriatal system. Therefore, future efforts using gene therapy for neurodegenerative diseases should consider means to enhance remaining dopamine neuron function and stop pathological propagation. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
|---|---|
| AbstractList | Neurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to protectdegenerating dopaminergic neurons.
Here, we performed post-mortem studies on two patients with advanced Parkinson's disease that survived 10 years following AAV-neurturin gene (Cere120) delivery to verify long-term effects of trophic factor neurturin.
Cere120 was delivered to the putamen bilaterally in one case and to the putamen plus substantia nigra bilaterally in the second. Immunohistochemistry was used to examine neurturin, Rearranged during transfection(RET), phosphor-S6, and tyrosine hydroxylase expressions, inflammatory reactions, and α-synuclein accumulation.
In both patients there was persistent, albeit limited, neurturin expression in the putamen covering 1.31% to 5.92% of the putamen. Dense staining of tyrosine hydroxylase-positive fibers was observed in areas that contained detectable neurturin expression. In substantia nigra, neurturin expression was detected in 11% of remaining melanin-containing neurons in the patient with combined putamenal and nigral gene delivery, but not in the patient with putamenal gene delivery alone. Tyrosine hydroxylase positive neurons were 66% to 84% of remaining neuromelanin neurons in substantia nigra with Cere120 delivery and 23% to 24% in substantia nigra without gene delivery. More RET and phosphor-S6 positive neurons were observed in substantia nigra following nigral Cere120. Inflammatory and Lewy pathologies were similar in substantia nigra with or without Cere120 delivery.
This study provides evidence of long-term persistent transgene expression and bioactivity following gene delivery to the nigrostriatal system. Therefore, future efforts using gene therapy for neurodegenerative diseases should consider means to enhance remaining dopamine neuron function and stop pathological propagation. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Neurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to protectdegenerating dopaminergic neurons.BACKGROUNDNeurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to protectdegenerating dopaminergic neurons.Here, we performed post-mortem studies on two patients with advanced Parkinson's disease that survived 10 years following AAV-neurturin gene (Cere120) delivery to verify long-term effects of trophic factor neurturin.OBJECTIVEHere, we performed post-mortem studies on two patients with advanced Parkinson's disease that survived 10 years following AAV-neurturin gene (Cere120) delivery to verify long-term effects of trophic factor neurturin.Cere120 was delivered to the putamen bilaterally in one case and to the putamen plus substantia nigra bilaterally in the second. Immunohistochemistry was used to examine neurturin, Rearranged during transfection(RET), phosphor-S6, and tyrosine hydroxylase expressions, inflammatory reactions, and α-synuclein accumulation.METHODSCere120 was delivered to the putamen bilaterally in one case and to the putamen plus substantia nigra bilaterally in the second. Immunohistochemistry was used to examine neurturin, Rearranged during transfection(RET), phosphor-S6, and tyrosine hydroxylase expressions, inflammatory reactions, and α-synuclein accumulation.In both patients there was persistent, albeit limited, neurturin expression in the putamen covering 1.31% to 5.92% of the putamen. Dense staining of tyrosine hydroxylase-positive fibers was observed in areas that contained detectable neurturin expression. In substantia nigra, neurturin expression was detected in 11% of remaining melanin-containing neurons in the patient with combined putamenal and nigral gene delivery, but not in the patient with putamenal gene delivery alone. Tyrosine hydroxylase positive neurons were 66% to 84% of remaining neuromelanin neurons in substantia nigra with Cere120 delivery and 23% to 24% in substantia nigra without gene delivery. More RET and phosphor-S6 positive neurons were observed in substantia nigra following nigral Cere120. Inflammatory and Lewy pathologies were similar in substantia nigra with or without Cere120 delivery.RESULTSIn both patients there was persistent, albeit limited, neurturin expression in the putamen covering 1.31% to 5.92% of the putamen. Dense staining of tyrosine hydroxylase-positive fibers was observed in areas that contained detectable neurturin expression. In substantia nigra, neurturin expression was detected in 11% of remaining melanin-containing neurons in the patient with combined putamenal and nigral gene delivery, but not in the patient with putamenal gene delivery alone. Tyrosine hydroxylase positive neurons were 66% to 84% of remaining neuromelanin neurons in substantia nigra with Cere120 delivery and 23% to 24% in substantia nigra without gene delivery. More RET and phosphor-S6 positive neurons were observed in substantia nigra following nigral Cere120. Inflammatory and Lewy pathologies were similar in substantia nigra with or without Cere120 delivery.This study provides evidence of long-term persistent transgene expression and bioactivity following gene delivery to the nigrostriatal system. Therefore, future efforts using gene therapy for neurodegenerative diseases should consider means to enhance remaining dopamine neuron function and stop pathological propagation. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.CONCLUSIONSThis study provides evidence of long-term persistent transgene expression and bioactivity following gene delivery to the nigrostriatal system. Therefore, future efforts using gene therapy for neurodegenerative diseases should consider means to enhance remaining dopamine neuron function and stop pathological propagation. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| Author | Kordower, Jeffrey H. Chu, Yaping |
| Author_xml | – sequence: 1 givenname: Yaping orcidid: 0000-0001-6573-9496 surname: Chu fullname: Chu, Yaping organization: ASU‐Banner Neurodegenerative Disease Research Center Tempe Arizona USA – sequence: 2 givenname: Jeffrey H. surname: Kordower fullname: Kordower, Jeffrey H. organization: ASU‐Banner Neurodegenerative Disease Research Center Tempe Arizona USA, School of Life Sciences Arizona State University Tempe Arizona USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37544016$$D View this record in MEDLINE/PubMed |
| BookMark | eNpt0bFuFDEQgGELBZFLoOAFkDug2GTGa599dOhyhEgBInIUVCufd6w47K4P25vourR0PGOeJAcJFIhqmm-mmH-P7QxxIMaeIxwggDjs23wgZgrNIzZBVWNlhNI7bALGqKpGo3bZXs6XAIgKp0_Ybq2VlIDTCbs6i7nc3vz8EFOhnp-XsQ2UefT8I42pjCkM_JgG4ssLSna94T4mfmbTtzDkOLzM_Chkspne8OV15Ofj6pJcyfw6lAuOcHvz4yvZlPl88XmBAvgRdeGK0uYpe-xtl-nZw9xnX94tlvP31emn45P529PK1QJK5aVTU5SgSbeALUhbG1BaS-eJXIt-1dJMtKARhJuBFR59W0tQ4LRGQ_U-e3V_d53i95FyafqQHXWdHSiOuRFG6lrKmdFb-uKBjque2madQm_Tpvnzqy14fQ9cijkn8n8JQvOrQ7Pt0PzusLWH_1gXii0hDiXZ0P1n4w5cr4s4 |
| CitedBy_id | crossref_primary_10_1016_j_omtn_2024_102332 crossref_primary_10_1016_S1474_4422_25_00125_5 crossref_primary_10_26508_lsa_202402922 crossref_primary_10_1002_mds_30193 crossref_primary_10_1080_14712598_2024_2386339 crossref_primary_10_1016_j_neurobiolaging_2025_02_003 crossref_primary_10_1038_s41434_024_00451_3 crossref_primary_10_1016_j_ymthe_2025_05_027 crossref_primary_10_3390_ijms252212369 crossref_primary_10_1177_1877718X241301041 crossref_primary_10_1016_j_neuroscience_2024_05_011 |
| Cites_doi | 10.1016/j.nbd.2015.03.023 10.1523/JNEUROSCI.18-13-04929.1998 10.1016/j.omtn.2017.06.011 10.1083/jcb.201009136 10.1038/nrn812 10.1016/S1474-4422(10)70254-4 10.1093/brain/awr149 10.1038/sj.mt.6300010 10.1046/j.1471-4159.1999.0730070.x 10.1016/S0896-6273(00)80318-9 10.1523/JNEUROSCI.0249-08.2008 10.1007/s00441-020-03235-4 10.3389/fnmol.2020.00064 10.1002/mds.23442 10.1016/j.ijbiomac.2021.05.194 10.1046/j.1460-9568.2000.00292.x 10.1002/ana.21032 10.1093/brain/awaa020 10.1093/brain/awz296 10.1016/j.expneurol.2009.07.002 10.1016/S0896-6273(00)81087-9 10.1016/j.nbd.2021.105298 10.1038/384467a0 10.1093/brain/aws133 10.1126/scitranslmed.3004676 10.1016/j.devbrainres.2003.11.006 10.1002/ana.24436 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| Copyright_xml | – notice: 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1002/mds.29518 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1531-8257 |
| EndPage | 1736 |
| ExternalDocumentID | 37544016 10_1002_mds_29518 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Michael J. Fox Foundation for Parkinson's Research grantid: Grant ID#MJFF-007847 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAYXX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CITATION CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O8X O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XV2 ZGI ZZTAW ~IA ~WT AAHHS ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE NPM RWD RWI WRC WUP YCJ 7X8 |
| ID | FETCH-LOGICAL-c320t-f4c561407e7d01d04a3805774cfeecd1fbde92d07102c90a2f1fd34050c7718e3 |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001041498600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0885-3185 1531-8257 |
| IngestDate | Sat Oct 11 07:09:53 EDT 2025 Wed Feb 19 02:23:28 EST 2025 Sat Nov 29 07:05:48 EST 2025 Tue Nov 18 21:38:38 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | gene therapy Parkinson's disease dopaminergic neuron neuroprotection neurotrophic factors |
| Language | English |
| License | 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c320t-f4c561407e7d01d04a3805774cfeecd1fbde92d07102c90a2f1fd34050c7718e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6573-9496 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.29518 |
| PMID | 37544016 |
| PQID | 2847344987 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2847344987 pubmed_primary_37544016 crossref_primary_10_1002_mds_29518 crossref_citationtrail_10_1002_mds_29518 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-01 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Movement disorders |
| PublicationTitleAlternate | Mov Disord |
| PublicationYear | 2023 |
| References | e_1_2_5_27_1 e_1_2_5_28_1 e_1_2_5_25_1 e_1_2_5_26_1 e_1_2_5_23_1 e_1_2_5_24_1 e_1_2_5_21_1 e_1_2_5_22_1 e_1_2_5_20_1 e_1_2_5_15_1 e_1_2_5_14_1 e_1_2_5_17_1 e_1_2_5_9_1 e_1_2_5_16_1 e_1_2_5_8_1 e_1_2_5_11_1 e_1_2_5_7_1 e_1_2_5_10_1 e_1_2_5_6_1 e_1_2_5_13_1 e_1_2_5_5_1 e_1_2_5_12_1 e_1_2_5_4_1 e_1_2_5_3_1 e_1_2_5_2_1 e_1_2_5_19_1 e_1_2_5_18_1 |
| References_xml | – ident: e_1_2_5_19_1 doi: 10.1016/j.nbd.2015.03.023 – ident: e_1_2_5_9_1 doi: 10.1523/JNEUROSCI.18-13-04929.1998 – ident: e_1_2_5_25_1 doi: 10.1016/j.omtn.2017.06.011 – ident: e_1_2_5_23_1 doi: 10.1083/jcb.201009136 – ident: e_1_2_5_5_1 doi: 10.1038/nrn812 – ident: e_1_2_5_18_1 doi: 10.1016/S1474-4422(10)70254-4 – ident: e_1_2_5_26_1 doi: 10.1093/brain/awr149 – ident: e_1_2_5_12_1 doi: 10.1038/sj.mt.6300010 – ident: e_1_2_5_10_1 doi: 10.1046/j.1471-4159.1999.0730070.x – ident: e_1_2_5_4_1 doi: 10.1016/S0896-6273(00)80318-9 – ident: e_1_2_5_16_1 doi: 10.1523/JNEUROSCI.0249-08.2008 – ident: e_1_2_5_3_1 doi: 10.1007/s00441-020-03235-4 – ident: e_1_2_5_27_1 doi: 10.3389/fnmol.2020.00064 – ident: e_1_2_5_20_1 doi: 10.1002/mds.23442 – ident: e_1_2_5_24_1 doi: 10.1016/j.ijbiomac.2021.05.194 – ident: e_1_2_5_6_1 doi: 10.1046/j.1460-9568.2000.00292.x – ident: e_1_2_5_11_1 doi: 10.1002/ana.21032 – ident: e_1_2_5_13_1 doi: 10.1093/brain/awaa020 – ident: e_1_2_5_15_1 doi: 10.1093/brain/awz296 – ident: e_1_2_5_22_1 doi: 10.1016/j.expneurol.2009.07.002 – ident: e_1_2_5_7_1 doi: 10.1016/S0896-6273(00)81087-9 – ident: e_1_2_5_14_1 doi: 10.1016/j.nbd.2021.105298 – ident: e_1_2_5_2_1 doi: 10.1038/384467a0 – ident: e_1_2_5_21_1 doi: 10.1093/brain/aws133 – ident: e_1_2_5_28_1 doi: 10.1126/scitranslmed.3004676 – ident: e_1_2_5_8_1 doi: 10.1016/j.devbrainres.2003.11.006 – ident: e_1_2_5_17_1 doi: 10.1002/ana.24436 |
| SSID | ssj0011516 |
| Score | 2.4875405 |
| Snippet | Neurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to... Neurturin is a member of the glial cell line-derived neurotrophic factor family of neurotrophic factors and has the potential to protectdegenerating... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 1728 |
| Title | Post‐Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37544016 https://www.proquest.com/docview/2847344987 |
| Volume | 38 |
| WOSCitedRecordID | wos001041498600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1531-8257 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011516 issn: 0885-3185 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3PaxQxFMeDbaX0Iv7u-qNEERRkNJOkk4k3Wbd4sEVKC-tpyOYHKu3MsjNbe_Tqv-lf4ksmGbfSgh68DMskO8vmM7y8JO99H0LPhOGqcCzPZkbqjCuhs1nBbOYoK1RpnaCGh2IT4uCgnE7lx1jDvQ3lBERdl-fncv5fUcM9gO1TZ_8B9_BQuAGfATpcATtc_wq8L7-b9TG0KUowbAvY5aLzW-tBadpHWng1gRBl6DOfYxKYaL0epz-yCfvu3xpvWb6GiI-wY5uTGB1Ryk8wcO3L8eRwklMCduvER3hcOCTeb4IYeedPgYLE5-C_jz8vg-1X8zRzhuybhfE121YSzGLqRNyVoGwIu4JJJVnSPIPlp7jUTve6r6emfUXBxStX-8Dfm58GNr46Lyz__lDK7ufe2LSGNqjYlWDONt4d7h1_GA6QwJEpkpAUoa-HX9pCm-m7Fz2RK5YXwc04uoluxPUBfttzvYWu2fo22tyPERB3ULeCF0e8uHF4wIs9XhzxYsCLB7zPWxzhvsGAFie02KPFOfn5_UeAiiNUnKDeRcd7k6Px-yxWzsg0o6TLHNde4ZUIKwzJDeGKleCYC66dtdrkbmaspCa4l1oSRV3uDAPfnWgBzopl99B63dR2G2FaSLLrgopRyRVxElx0zQSRTM-U4XaEXqRRrHSUlffVTU6qXhCbVjD2VRj7EXo6dJ33WiqXdXqSUFRg6fzxlapts4RmcKQY57IUI3S_ZzQ8JjF9cGXLQ7T1-z19hNa7xdI-Rtf1WfelXeygNTEtd-JL9AvTUHkS |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Post-Mortem+Studies+of+Neurturin+Gene+Therapy+for+Parkinson%27s+Disease%3A+Two+Subjects+with+10%E2%80%89Years+CERE120+Delivery&rft.jtitle=Movement+disorders&rft.au=Chu%2C+Yaping&rft.au=Kordower%2C+Jeffrey+H&rft.date=2023-09-01&rft.eissn=1531-8257&rft_id=info:doi/10.1002%2Fmds.29518&rft_id=info%3Apmid%2F37544016&rft.externalDocID=37544016 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |